Skip to content
Use your HSA or FSA funds

Condition report · Gastrointestinal

Hereditary Pancreatitis

Whole genome sequencing evaluates PRSS1, SPINK1, CTRC, and CFTR simultaneously, the complete molecular panel for hereditary pancreatitis, enabling risk-stratified pancreatic cancer surveillance and informed genetic counseling.

A condition report looks for rare variants known to cause the conditions it covers.

Included with every kit

From $449Free shipping · Results in 6–8 weeks

Get my Genome Test

About this condition

An inflammation of the pancreas, an organ producing digestive enzymes and hormones, characterized by severe abdominal pain, nausea, and vomiting.

Hereditary pancreatitis (HP) is an autosomal dominant condition caused primarily by gain-of-function variants in PRSS1 (cationic trypsinogen, chromosome 7q34). PRSS1 variants prevent trypsin autoinactivation, leading to premature intrapancreatic trypsinogen activation and recurrent pancreatic autodigestion. The most common pathogenic variants are p.Arg122His (R122H) and p.Asn29Ile (N29I). Additional genes contribute to pancreatitis susceptibility: SPINK1 (serine protease inhibitor Kazal type 1, a trypsin inhibitor), CTRC (chymotrypsin C, involved in trypsin degradation), and CFTR (cystic fibrosis transmembrane conductance regulator; heterozygous CFTR variants increase chronic pancreatitis risk).

HP typically presents with the first episode of acute pancreatitis in childhood (median age 10 years). Recurrent episodes of acute pancreatitis progress to chronic pancreatitis with exocrine insufficiency (fat malabsorption, steatorrhea, nutritional deficiency) and endocrine insufficiency (pancreatogenic diabetes). The defining clinical concern is a dramatically elevated lifetime risk of pancreatic adenocarcinoma, approximately 40% by age 70, representing a 50-80x increased risk compared to the general population. This is the highest known familial risk for pancreatic cancer.

The International Cancer of the Pancreas Screening (CAPS) consortium and NCCN guidelines recommend annual pancreatic cancer surveillance, endoscopic ultrasound (EUS) and/or magnetic resonance cholangiopancreatography (MRCP), beginning at age 40 (or 20 years after symptom onset, whichever is earlier) for patients with confirmed hereditary pancreatitis. Several early-stage pancreatic cancers have been detected through these surveillance programs, representing a survival benefit that would not be possible without screening. Enrollment in formal surveillance programs requires molecular confirmation of the HP diagnosis.

CFTR heterozygous carriers (who do not have cystic fibrosis) have an approximately 2-4x increased risk of chronic pancreatitis, especially when carrying a second susceptibility variant in SPINK1 or CTRC.

The condition we analyse

Inflammation of the pancreas.

What a diagnosis changes

Pain management; pancreatic enzyme replacement for exocrine insufficiency; diabetes management; annual EUS/MRCP surveillance for pancreatic cancer beginning at age 40; total pancreatectomy with islet autotransplantation (TPIAT) in refractory cases

Genes analysed

Also known as

inflammation of pancreas; pancreas inflammation

Includes 15 related subtypes ↓
  • acute hemorrhagic pancreatitis
  • acute necrotizing pancreatitis
  • acute pancreatitis
  • alcoholic pancreatitis
  • autoimmune pancreatitis
  • autoimmune pancreatitis type 1
  • autoimmune pancreatitis type 2
  • autosomal recessive hereditary chronic pancreatitis
  • chronic pancreatitis
  • early-onset idiopathic chronic pancreatitis
  • hereditary chronic pancreatitis
  • idiopathic chronic pancreatitis
  • late-onset idiopathic chronic pancreatitis
  • thiopurine immunosuppressant-induced pancreatitis
  • tropical pancreatitis
MONDO:0004982MedGen 14586

Why whole genome sequencing

Recurrent pancreatitis in a young person has multiple genetic causes. PRSS1, SPINK1, CTRC, and CFTR must all be evaluated, along with gene-gene interactions, to determine the complete genetic pancreatitis risk profile.

A 40% lifetime pancreatic cancer risk is actionable: surveillance programs detect cancer at curable stages

Pancreatic adenocarcinoma is the most lethal major cancer: 5-year survival is approximately 12% for all stages and approximately 44% for localized disease. In hereditary pancreatitis, the 40% lifetime risk justifies annual EUS/MRCP surveillance beginning at age 40 (CAPS consensus). Multiple early-stage pancreatic cancers have been detected through HP-specific screening programs, offering surgical resection with curative intent. Without molecular HP diagnosis, patients may not be referred to these surveillance programs, instead receiving standard-risk monitoring that does not include pancreatic imaging.

Gene-gene interactions determine whether a SPINK1 carrier develops pancreatitis: multiple genes must be evaluated together

SPINK1 variants (particularly p.Asn34Ser, carrier frequency approximately 1-3% in European populations) are not fully penetrant; most carriers never develop pancreatitis. However, SPINK1 variants dramatically increase pancreatitis risk in combination with CFTR heterozygous variants, CTRC variants, or environmental factors (alcohol use, smoking). This gene-gene interaction means that evaluating a single pancreatitis gene in isolation provides incomplete risk information. Whole genome sequencing evaluates PRSS1, SPINK1, CTRC, CFTR, and additional susceptibility loci simultaneously, capturing the full genetic risk architecture.

More conditions

All conditions →

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. Physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Free shipping · Results in 6–8 weeks

Get my Genome Test